

Medical drug benefit Clinical Criteria updates

Please note, this communication applies to Anthem HealthKeepers Plus, Medallion and Anthem HealthKeepers Plus, Commonwealth Coordinated Care Plus (Anthem CCC Plus) offered by HealthKeepers, Inc.

On August 21, 2020 and May 21, 2021, the Pharmacy and Therapeutic (P&T) Committee approved the following *Clinical Criteria* applicable to the Anthem HealthKeepers Plus **medical drug benefit** for HealthKeepers, Inc. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit *Clinical Criteria* to search for specific policies. If you have questions or would like additional information, use this **email**.

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

Effective date	Document number	Clinical Criteria title	New or revised
September 5, 2021	*ING-CC-0196	Zynlonta (loncastuximab tesirine-lpyl)	New
September 5, 2021	*ING-CC-0197	Jemperli (dostarlimab)	New
September 5, 2021	*ING-CC-0198	Relizorb (immobilized lipase) cartridge	New
September 5, 2021	*ING-CC-0199	Empaveli (pegcetacoplan)	New
September 5, 2021	ING-CC-0163	Durysta (bimatoprost implant)	Revised
September 5, 2021	*ING-CC-0111	Nplate (romiplostim)	Revised
September 5, 2021	*ING-CC-0137	Cablivi (caplacizumab-yhdp)	Revised
September 5, 2021	ING-CC-0165	Trodelvy (sacituzumab govitecan)	Revised
September 5, 2021	*ING-CC-0124	Keytruda (pembrolizumab)	Revised
September 5, 2021	*ING-CC-0128	Tecentriq (atezolizumab)	Revised
September 5, 2021	ING-CC-0099	Abraxane (paclitaxel, protein bound)	Revised
September 5, 2021	ING-CC-0098	Doxorubicin Liposome (Doxil, Lipodox)	Revised
September 5, 2021	*ING-CC-0107	Bevacizumab for Non-Ophthalmologic Indications	Revised
September 5, 2021	ING-CC-0127	Darzalex (daratumumab)	Revised

https://providers.anthem.com/va

Effective date	Document number	Clinical Criteria title	New or revised
September 5, 2021	ING-CC-0142	Somatuline Depot (lanreotide)	Revised
September 5, 2021	*ING-CC-0114	Jevtana (cabazitaxel)	Revised
September 5, 2021	ING-CC-0161	Sarclisa (isatuximab-irfc)	Revised
September 5, 2021	ING-CC-0120	Kyprolis (carfilzomib)	Revised
September 5, 2021	*ING-CC-0145	Libtayo (cemiplimab-rwlc)	Revised
September 5, 2021	ING-CC-0151	Yescarta (axicabtagene ciloleucel)	Revised
September 5, 2021	ING-CC-0150	Kymriah (tisagenlecleucel)	Revised
September 5, 2021	ING-CC-0125	Opdivo (nivolumab)	Revised
September 5, 2021	*ING-CC-0032	Botulinum Toxin	Revised
September 5, 2021	*ING-CC-0160	Vyepti (eptinezumab)	Revised
September 5, 2021	*ING-CC-0052	Dihydroergotamine (DHE) injection	Revised
September 5, 2021	*ING-CC-0066	Monoclonal Antibodies to Interleukin-6	Revised
September 5, 2021	*ING-CC-0102	GNRH Analogs for Oncologic Indications	Revised
September 5, 2021	*ING-CC-0020	Tysabri (natalizumab)	Revised

If you have any questions about this communication, call Anthem HealthKeepers Plus, Medallion Provider Services at **800-901-0020** or Anthem CCC Plus Provider Services at **855-323-4687**.